drugset / Trial / NCT02284035
Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine
RandomizedParallel-groupOpen-labelTreatment
Summary
A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combination therapy in HIV-infected patients with prolonged virological suppression
Timeline
- Start
- 2015-09-27
- Primary completion
- 2017-02-28
- Completion
- 2017-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | 150 mg | Oral |
| Subject | Raltegravir | Other / unclassified | 300 mg | Oral |
| Comparator | ABC | Unknown | — | — |
| Comparator | ATV | Unknown | — | — |
| Comparator | DRV | Unknown | — | — |
| Comparator | DTG | Unknown | — | — |
| Comparator | EFV | Unknown | — | — |
| Comparator | EVG | Unknown | — | — |
| Comparator | FTC | Unknown | — | — |
| Comparator | LPV | Unknown | — | — |
| Comparator | RAL | Unknown | — | — |
| Comparator | RPV | Unknown | — | — |
| Comparator | TDF | Unknown | — | — |
| Comparator | cobi | Unknown | — | — |
| Comparator | r | Unknown | — | — |